Skip to main content
SpringerLink
Log in

The Immunology and Immunotherapy of Human Malignant Melanoma

  • Chapter
Clinical Management of Malignant Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 21))

Abstract

Malignant melanoma is a disease which has excited the interest of immunologists for many years. Some of this interest is based on clinical observations, such as spontaneous regression, or the results of clinical trials, such as immunocompetence testing or response to immunotherapy. On the other hand, some interest seems to be mainly dependent on the coincidental fact that melanoma cells grow well in tissue culture and are therefore frequently available for in vitro studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Nathanson L: Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 44: 67–76, 1976.

    PubMed  CAS  Google Scholar 

  2. Everson TC: Spontaneous regression of cancer. Ann NY Acad Sci 114: 721–735, 1964.

    Article  Google Scholar 

  3. Epstein WL, Sagebeil R, Spitler L, et al: Halo nevi and melanoma. JAMA 225: 373–377, 1973.

    Article  PubMed  CAS  Google Scholar 

  4. Smith JL Jr, Stehlin JS Jr: Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18: 1399–1415, 1965.

    Article  PubMed  Google Scholar 

  5. Fowler GL: Enhancement of natural resistance to malignant melanoma with pecial reference to the beneficial effects of concurrent infections and bacterial toxin therapy. Monograph #9, New York, Cancer Research Inst, 1969.

    Google Scholar 

  6. Ikonopisov RL, Oreshkov VI: Possible immunological significance of hepatomegaly and splenomegaly as recorded by hepatic gamma scanning in patients with malignant melanoma. Tumori 60: 99–104, 1974.

    PubMed  CAS  Google Scholar 

  7. Eilber FR, Morton DL: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25: 362–367, 1970.

    Article  PubMed  CAS  Google Scholar 

  8. Pinsky CM, Oettgen HF, el Domeiri A, et al: Delayed hypersensitivity reactions in patients with cancer. Proc Amer Assoc Cancer Res 13: 100, 1971 (abstract).

    Google Scholar 

  9. Eilber FR, Nizze JA, Morton DL: Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course. Cancer 35: 660–665, 1975.

    Article  PubMed  CAS  Google Scholar 

  10. Camacho ES, Pinsky CM, Braun DW, et al: DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 47: 2446–2450, 1981.

    Article  PubMed  CAS  Google Scholar 

  11. Golub SH, O’Connell TX, Morton DL: Correlation of in vivoand in vitroassays of immunocompetence in cancer patients. Cancer Res 34: 1833–1837, 1974.

    PubMed  CAS  Google Scholar 

  12. Lee YN, Sparks FC, Eilber FR, Morton DL: Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer 35: 748–755, 1975.

    Article  PubMed  CAS  Google Scholar 

  13. Tilden AB, Balch CM: Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 90: 77–84, 1981.

    PubMed  CAS  Google Scholar 

  14. de Gast GC, The TH, Koops HS, et al: Humoral and Cell-mediated immune response in patients with malignant melanoma: I. In vitrolymphocyte reactivity to PHA and antigens following immunization. Cancer 36: 1289–1297, 1975.

    Article  PubMed  Google Scholar 

  15. Gersten MJ, Hadden EM, Kaplan MH, et al: Immunologic defects in melanoma patients: Lack of effect of BCG therapy. Clin Bull 7: 63–69, 1977.

    PubMed  CAS  Google Scholar 

  16. Karavodin LM, Giuliano AE, Golub SH: T lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother 11: 251–254, 1981.

    Article  Google Scholar 

  17. Glasgow AH, Nimberg RB, Menzoian JO, et al: Associations of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med 291:1263– 1267, 1974.

    Article  PubMed  CAS  Google Scholar 

  18. Currie GA, Hedley DW: Monocytes and macrophages in malignant melanoma: I. Peripheral blood macrophage precursors. Br J Cancer 36: 1–6, 1977.

    Article  PubMed  CAS  Google Scholar 

  19. Finelt M, Hoffmann MK: A human monocyte function test: Release of B-cell diferentiation factor (BDF). Clin Immunol Immunopath 12: 281–288, 1979.

    Article  CAS  Google Scholar 

  20. Snyderman R, Seigler HF, Meadows L: Abnormalities of monocyte chemotaxis in patients with melanoma: Effects of immunotherapy in tumor removal. JNCI 58: 37–41, 1977.

    PubMed  CAS  Google Scholar 

  21. Thatcher N, Hashmi K, Chang J, et al: Anti-T antibody in malignant melanoma patients: Influence of response and survival following chemotherapy - changes in serum levels following C. parvum, BCG immunization. Cancer 46: 1378–1382, 1980.

    Article  PubMed  CAS  Google Scholar 

  22. Kaplan MH, Armstrong D, Pinsky C: Antibody responses to mycobacterial antigens in patients immunized with BCG for the treatment of neoplastic disease. Cancer 46:2195– 2202, 1980.

    Article  PubMed  CAS  Google Scholar 

  23. Lewis MG, Lond MB: Possible immunological factors in human malignant melanoma in Uganda. Lancet ii: 921–922, 1967.

    Google Scholar 

  24. Morton DL, Malmgren RA, Holmes EC, Ketcham AS: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64: 233–240, 1968.

    PubMed  CAS  Google Scholar 

  25. Oettgen HF, Aoki T, Old LJ, et al: Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J Nat Cancer Inst 41: 827–843, 1968.

    PubMed  CAS  Google Scholar 

  26. Hertz KC, Kirkpatrick CH, Katz SI: Autoimmune vitiligo: Detection of antibodies to melanin-producing cells. N Engl J Med 297: 634–637, 1977.

    Article  PubMed  CAS  Google Scholar 

  27. Roenigk HH, Deodar SD, Krebs JA, Barna B: Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus. Arch Dermatol 111: 720–725, 1975.

    Article  PubMed  CAS  Google Scholar 

  28. Murray E, Ruygrok S, Milton W, Hersey P: Analysis of serum blocking factors against leukocyte-dependent antibody in melanoma patients. Int J Cancer 21: 578–587, 1978.

    Article  PubMed  CAS  Google Scholar 

  29. Minden P, Jarrett C, McClatchy JK, et al: Antibodies to melanoma cell and BCG antigens in sera from tumour–free individuals and from melanoma patients. Nature 263: 774–777, 1976.

    Article  PubMed  CAS  Google Scholar 

  30. Ferrone S, Pellegrino MA: Cytotoxic antibodies to cultured melanoma cells in sera of melanoma patients. J Natl Cancer Inst 58: 20–23, 1977.

    Google Scholar 

  31. Kilpatrick RJ, Seigler HF: Specific cytotoxic antibody in the sera of patients with melanoma. J Surg Res 21: 301–305, 1976.

    Article  PubMed  CAS  Google Scholar 

  32. Livingston PO, Michitsch R, Shiku H, et al: Antibody-dependent cell-mediated cytotoxicity for cultured autologous melanoma cells. Cell Immunol 64: 131–143, 1981.

    Article  PubMed  CAS  Google Scholar 

  33. Kodera Y, Bean MA: Antibody–dependent cell–mediated cytotoxicity for human monolayer target cells bearing blood group and transplantation antigens and for melanoma cells. Int J Cancer 16: 579–592, 1975.

    Article  PubMed  CAS  Google Scholar 

  34. Hersey P, Edwards A, Adams E, et al: Antibody-dependent cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis. Lancet i: 825–827, 1976.

    Google Scholar 

  35. Peter HH, Kalden JR, Seeland P, et al: Humoral and cellular immune reactions ‘in vitro’ against allogeneic and autologous human melanoma cells. Clin Exp Immunol 20: 193–207, 1975.

    PubMed  CAS  Google Scholar 

  36. Jones PC, Sze LL, Liu PY, et al: Prolonged survival of melanoma patients with elevated IgM antibody to oncofetal antigen. JNCI 66: 249–254, 1981.

    PubMed  CAS  Google Scholar 

  37. Teshima H, Wanebo H, Pinsky C, et al: Circulating immune complexes detected by 125I–Clq deviation test in sera of cancer patients. J Clin Invest 59: 1134–1142, 1977.

    Article  PubMed  CAS  Google Scholar 

  38. Gupta RK, Theofilopoulos AN, Dixon FJ, Morton DL: Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol Immunother 6: 211–221, 1979.

    Google Scholar 

  39. Kristensen E, Brandslund I, Nielsen H, Svehag SE: Prognostic value of assays for circulating immune complexes and natural cytotoxicity in malignant skin melanoma (stages I and II). Cancer Immunol Immunother 9: 31–36, 1980.

    Article  Google Scholar 

  40. Morgan AC, Rossen RD, McCormick, Stehlin JS Jr, Giovanella BC: ‘Hidden’ cytotoxic antibodies that react with allogeneic cultured fetal and tumor cells contained in soluble immune complexes from normal human sera. Cancer Res 42: 881–887, 1982.

    PubMed  CAS  Google Scholar 

  41. Bluming AZ, Vogel CL, Ziegler JL, et al: Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: A second look. J Natl Cancer Inst 48: 17–24, 1972.

    PubMed  CAS  Google Scholar 

  42. Holmes EC, Roth JA, Morton DL: Delayed cutaneous hypersensitivity reactions to melanoma antigen. Surgery 78: 160–164, 1975.

    PubMed  CAS  Google Scholar 

  43. Mukheiji B, Rothman L, Ucci A, et al: Delayed–type cutaneous hypersensitivity to melanoma antigens and its implication in active specific immunotherapy in cancer. Cancer Immunol Immunother 8: 149–155, 1980.

    Google Scholar 

  44. Gorodilova VV, Hollinshead A: Melanoma antigens that produce cell–mediated immune responses in melanoma patients: Joint U.S.-U.S.S.R. study. Science 190: 391–392, 1975.

    Article  PubMed  CAS  Google Scholar 

  45. Jehn UW, Nathanson L, Schwartz RS, Skinner M: In vitrolymphocyte stimulation by a soluble antigen from malignant melanoma. N Engl J Med 283: 329–333, 1970.

    Article  PubMed  CAS  Google Scholar 

  46. Nagel GA, St.-Arneault G, Holland JF, et al: Cell–mediated immunity against malignant melanoma in monozygous twins. Cancer Res 30: 1828–1832, 1970.

    PubMed  CAS  Google Scholar 

  47. Guerry D, IV, Alexander MA, Fuhrer JP, et al: HLA-DR-dependent autologous T-cell proliferation induced by cultured primary melanoma. In: Pigment cell 1981, Seiji M (ed). Tokyo: University of Tokyo Press, 1981.

    Google Scholar 

  48. Cochran AJ, Spilg WGS, Mackie RM, Thomas CE: Postoperative depression of tumor– directed cell–mediated immunity in patients with malignant disease. Br Med J 4: 67–70, 1972.

    Article  PubMed  CAS  Google Scholar 

  49. Currie GA, Basham C: Serum mediated inhibition of the immunological reactions of the patient to his own tumour: A possible role for circulating antigen. Br J Cancer 26: 427–438, 1972.

    Article  PubMed  CAS  Google Scholar 

  50. Hellstrom I, Hellstrom KE: Some recent studies on cellular immunity to human melanomas. Fed Proc 32: 156–159, 1973.

    PubMed  CAS  Google Scholar 

  51. Unsgaard B, O’Toole C: The influence of tumor burden and therapy on cellular cytotoxicity responses in patients with ocular and skin melanoma. Br J Cancer 31: 301–316, 1975.

    Article  PubMed  CAS  Google Scholar 

  52. Mukheiji B, Vassos D, Flowers A, et al: Variables and specificity of in vitrolymphocyte-mediated cytotoxicity in human melanoma. Cancer Res 35: 3721–3730, 1975.

    Google Scholar 

  53. Livingston PO, Shiku H, Bean MA, et al: Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int J Cancer 24: 34–44, 1979.

    Article  PubMed  CAS  Google Scholar 

  54. Mukheiji B, Flowers A, Rothman L, Nathanson L: Spontaneous in vitrocytotoxicity against autochthonous human melanoma cells. J Immunol 124: 412–417, 1980.

    Google Scholar 

  55. Metzgar RS, Bergoc PM, Moreno MA, Seigler HF: Brief Communication: Melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines. JNCI 50: 1065–1068, 1973.

    PubMed  CAS  Google Scholar 

  56. Bruggen J, Macher E, Sorg C: Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma. Cancer Immunol Immunother 10: 121–127, 1981.

    Article  Google Scholar 

  57. Carrel S, Theilkaes L: Evidence for a tumor–associated antigen in human malignant melanoma. Nature 242: 609–610, 1973.

    Article  PubMed  CAS  Google Scholar 

  58. Gupta RK, Silver HKB, Morton DL: Production and characterization of xenogeneic anti-sera to tumor–associated antigen(s). J Surg Oncol 13: 75–89, 1980.

    Article  PubMed  CAS  Google Scholar 

  59. Ferrone S, Imai K, McGabe RP, et al: Production, characterization, and use of xenoantisera to human melanoma-associated antigens. In: Serologic analysis of human cancer antigens. New York: Academic Press, Inc, 1980, pp 445–459.

    Google Scholar 

  60. Nathanson L, Jehn U, Schwartz RS: Disappearance of a tumor-associated antigen in malignant melanoma after imidazole carboxamide therapy. Cancer 27: 411–415, 1971.

    Article  PubMed  CAS  Google Scholar 

  61. Irie RF, Irie K, Morton DL: A membrane antigen common to human cancer and fetal brain tissues. Cancer Res 36: 3510–3517, 1976.

    PubMed  CAS  Google Scholar 

  62. Hersey P, Honeyman M, Adams EE, McCarthy WH: Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera. Int J Cancer 18: 564–573, 1976.

    Article  PubMed  CAS  Google Scholar 

  63. Carey TE, Takahashi T, Resnick LA, et al: Cell Surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci 73: 3278–3282, 1976.

    Article  PubMed  CAS  Google Scholar 

  64. Old LJ: Cancer immunology: The search for specificity - G.H.A. Clowes Memorial Lecture. Cancer Res 41: 361–375, 1981.

    PubMed  CAS  Google Scholar 

  65. Albino AP, Lloyd KO, Houghton AN, et al: Heterogeneity in surface antigens and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient: Implications for the study of tumor antigens. J Exp Med 154: 1764–1778, 1981.

    Article  PubMed  CAS  Google Scholar 

  66. Houghton AN, Taormina MC, Ikeda H,et al: Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci 77: 4260–4264, 1980.

    Article  PubMed  CAS  Google Scholar 

  67. Watanabe T, Pukel CS, Takeyama H, et al: Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 156: 1884–1889, 1982.

    Article  PubMed  CAS  Google Scholar 

  68. Grimm EA, Silver HKB, Roth JA, et al: Detection of tumor–associated antigen in human melanoma cell line supernatants. Int J Cancer 17: 559–564, 1976.

    Article  PubMed  CAS  Google Scholar 

  69. Gupta RK, Irie RF, Chee DO, et al: Demonstration of two distinct antigens in spent tissue culture medium of a human malignant melanoma cell line. J Natl Cancer Inst 63: 347–356, 1979.

    PubMed  CAS  Google Scholar 

  70. Hersey P, Murray E, McCarthy WH: Evaluation of antibody inhibition assays of melanoma antigens in sera to monitor tumor growth in melanoma patients. Cancer Immunol Immunother 10: 67–74, 1981.

    Article  Google Scholar 

  71. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497, 1975.

    Article  PubMed  CAS  Google Scholar 

  72. Koprowski H, Steplewski Z, Herlyn D, Herlyn M: Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci 75: 3405–3409, 1978.

    Article  PubMed  CAS  Google Scholar 

  73. Yeh MY, Hellstrom I, Brown JP, et al: Cell Surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci 76: 2927–2931, 1979.

    Article  PubMed  CAS  Google Scholar 

  74. Dippold WG, Lloyd KO, Li LTC, et al: Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci 77: 6114–6118, 1980.

    Article  PubMed  CAS  Google Scholar 

  75. Imai K, Molinaro GA, Ferrone S: Monoclonal antibodies to human melanoma-associated antigens. Transplant Proc 12: 380–383, 1980.

    PubMed  CAS  Google Scholar 

  76. Morgan AC, Galloway DR, Reisfeld RA: Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1: 27–36, 1981.

    Article  PubMed  CAS  Google Scholar 

  77. Irie RF, Sze LL, Saxton RE: Human antibody to OFA–I, a tumor antigen, produced in vitroby Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc Natl Acad Sci 79: 5666–5670, 1982.

    Article  PubMed  CAS  Google Scholar 

  78. Houghton AN, Brooks H, Cote RJ, et al: Detection of cell surface and intracellular antigens by human monoclonal antibodies: Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med 158: 53–65, 1983.

    Article  PubMed  CAS  Google Scholar 

  79. Wilson BS, Indiveri F, Molinaro GA, et al: Characterization of DR antigens on cultured melanoma cells by using monoclonal antibodies. Transplant Proc 12: 125–129, 1980.

    PubMed  CAS  Google Scholar 

  80. Brown JP, Hewick RM, Hellstrom I, et al: Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature 296: 171–173, 1982.

    Article  PubMed  CAS  Google Scholar 

  81. Houghton AN, Eisinger M, Albino AP, et al: Surface antigens of melanocytes and melanomas: Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156: 1755–1766, 1982.

    Article  PubMed  CAS  Google Scholar 

  82. Pukel CS, Lloyd KO, Travassos LR, et al: GD3, a prominent ganglioside of human melanoma: Detection and characterization by mouse monoclonal antibody. J Exp Med 155: 1133–1147, 1982.

    Article  PubMed  CAS  Google Scholar 

  83. Cahan LD, Irie RF, Singh R, et al: Identification of a human neuroectodermal tumor antigen (OFA–I–2) as ganglioside GD2. Proc Natl Acad Sci 79: 7629–7633, 1982.

    Article  PubMed  CAS  Google Scholar 

  84. Tai T. Paulson JC, Cahan LD, Irie RF: GM2 ganglioside as human tumor antigen (OFA- 1-1). Proc Amer Assoc Cancer Res 24: 226, 1983.

    Google Scholar 

  85. Ladisch S, Gillard B, Wong C, Ulsh L: Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 43: 3808–3813, 1983.

    PubMed  CAS  Google Scholar 

  86. Bumol TF, Wang QC, Reisfeld RA, Kaplan NO: Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivotumor growth. Proc Natl Acad Sci 80: 529–533, 1983.

    Article  PubMed  CAS  Google Scholar 

  87. Dippold W, Knuth A, zum Buschenfelde KHM: Cytostatic effect of monoclonal anti-GD3- ganglioside antibody on the growth of human melanoma cells in vitro. Proc Amer Assoc Cancer Res 24: 210, 1983.

    Google Scholar 

  88. Hellstrom I, Brown JP, Hellstrom KE: Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity. J Immunol 127: 157–160, 1981.

    PubMed  CAS  Google Scholar 

  89. Hellstom I, Hellstom KE, Yeh MY: Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas. Int J Cancer 27:281– 285, 1981.

    Article  Google Scholar 

  90. Schulz G, Bumol TF, Reisfeld RA: Monoclonal antibody directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci (In Press).

    Google Scholar 

  91. Wilson BS, Imai K, Natali PG, Ferrone S: Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28: 293–300, 1981.

    Article  PubMed  CAS  Google Scholar 

  92. Garrigues HJ, Tilgen W, Hellstom I, et al: Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer 29:511– 515, 1982.

    Article  PubMed  CAS  Google Scholar 

  93. Real F, Houghton A, Urmacher C, et al: Monoclonal antibodies detecting melanoma antigens in tissue sections. Proc Amer Assoc Cancer Res 23: 255, 1982.

    Google Scholar 

  94. Larson SM, Brown JP, Wright PW, et al: Imaging of melanoma with 1–131–labeled monoclonal antibodies. J Nucl Med 24: 123–129, 1983.

    PubMed  CAS  Google Scholar 

  95. Morton DL, Eilber FR, Malmgren RA, Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68: 158–164, 1970.

    PubMed  CAS  Google Scholar 

  96. Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 56: 659–665, 1972.

    PubMed  CAS  Google Scholar 

  97. Pinsky CM, Hirshaut Y, Oettgen HF: Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr 39: 225–228, 1973.

    PubMed  CAS  Google Scholar 

  98. Israel L, Depierre A, Edelstein R, et al: Effect of intranodular BCG in 22 melanoma patients. Pan Med 17: 187–188, 1975.

    CAS  Google Scholar 

  99. Mastrangelo MJ, Sulit HL, Prehn LM, et al: Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37: 684–692, 1976.

    Article  PubMed  CAS  Google Scholar 

  100. Mastrangelo MJ, Bellet RF, Berkelhammer J, Clark WH: Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36: 1305–1308, 1975.

    Article  PubMed  CAS  Google Scholar 

  101. McKhann CF, Hendrickson CG, Spitler LE, et al: Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection. Cancer 35: 514–520, 1975.

    Article  PubMed  CAS  Google Scholar 

  102. Sparks FC, Silverstein MJ, Hunt JS, et al: Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289: 827–830, 1973.

    Article  PubMed  CAS  Google Scholar 

  103. Rosenberg EB, Kanner SP, Schwartzman RJ, Colsky J: Systemic infection following BCG therapy. Arch Intern Med 134: 769–770, 1964.

    Article  Google Scholar 

  104. Serrou B, Michel H, DuBois JB, Serre A: Granulomatous hepatitis caused by BCG injection during immunotherapy of a malignant melanoma. Biomedicine 23: 236–240, 1975.

    PubMed  CAS  Google Scholar 

  105. Malek-Mansour S: Remission of melanoma with D.B.C.B. treatment. Lancet: 503–504, 1973.

    Google Scholar 

  106. Yamamura Y, Yoshizaki K, Azuma I, et al: Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton. Gann 66: 355–363, 1975.

    PubMed  CAS  Google Scholar 

  107. Richman SP, Mavligit GM, Wolk R, et al: Epilesional scarification: Preliminary report of a new approach to local immunotherapy with BCG. JAMA 234: 1233–1235, 1975.

    Article  PubMed  CAS  Google Scholar 

  108. Cohen MH, Jessup JM, Felix EL, et al: Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 41: 2456–2463, 1978.

    Article  PubMed  CAS  Google Scholar 

  109. Krown SE, Hilal EY, Pinsky CM, et al: Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer 42: 2648–2660, 1978.

    Article  PubMed  CAS  Google Scholar 

  110. Ishihara K, Hayasaka K: Immunotherapy of malignant melanoma. Gann 21: 231–235, 1978.

    Google Scholar 

  111. Kerr D, Krown SE, Livingston PO, et al: Treatment of melanoma skin metastases with intralesional DNCB. Proc Amer Soc Clin Oncol 22: 528, 1981.

    Google Scholar 

  112. Cunningham-Rundles WF, Hirshaut Y, Pinsky CM, Oettgen HF: Phase I trial of intralesional Corynebacterium parvum. Clin Res 23: 337A, 1975.

    Google Scholar 

  113. Storm FK, Sparks FC, Morton DL: Treatment for melanoma of the lower extremity with intralesional injection of Bacille Calmette Guerin and hyperthermic perfusion. Surg gynecol Obstet 149: 17–21, 1979.

    PubMed  CAS  Google Scholar 

  114. Lieberman R, Epstein W, Fudenberg HH: Immunopathological changes in patients with cutaneous malignant melanoma following intratumoral inoculation of BCG: Correlation with cell-mediated immunity. Int J Cancer 14: 401–416, 1974.

    Article  PubMed  CAS  Google Scholar 

  115. Khalil A, Rappaport H, Misset JL: Kinetics of histologic changes in human melanoma after local Immunotherapy with BCG. Cancer Immunol Immunother 1: 193–196, 1976.

    Article  Google Scholar 

  116. Hunter–Craig I, Newton KA, Westbury G, Lacey BW: Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br Med J 2: 512–515, 1970.

    Article  Google Scholar 

  117. Everall JD, Ward J, O’Doherty CJ, Dowd PM: Treatment of primary melanoma by intralesional vaccinia before excision. Lancet ii: 583–586, 1975.

    Google Scholar 

  118. Rosenberg SA, Rapp H, Terry W, et al: Intralesional BCG therapy of patients with primary Stage I melanoma. In: Immunotherapy of human cancer, Terry WD, Rosenberg SA (eds). Amsterdam: Elsevier North Holland, Inc., 1982, pp 239–244.

    Google Scholar 

  119. Silberman AW, Morton DL: Adjuvant therapy following surgery of primary malignant melanoma. In: Malignant melanoma 1, Costanzi JJ (ed). The Hague: Martinus Nijhoff Publishers, 1983, pp 207–223.

    Chapter  Google Scholar 

  120. Pinsky CM, Oettgen HF: Surgical adjuvant therapy for malignant melanoma. Surg Clin North Am 61: 1259–1265, 1981.

    PubMed  CAS  Google Scholar 

  121. MacGregor AB, Falk RE, Landi S, Ambus U, Langer B: Oral Bacille Calmette Guerin immunostimulation in malignant melanoma. Surg Gynecol Obstet 141: 747–754, 1975.

    PubMed  CAS  Google Scholar 

  122. Camacho F, Pinsky C, Krown S, et al: Oral administration of BCG in 26 patients with metastatic malignant melanoma. Proc Amer Assoc Cancer Res 20: 116, 1979.

    Google Scholar 

  123. Varella AD, Bandiera DC, DeAmorin AR, et al: Treatment of disseminated malignant melanoma with high–dose oral BCG. Cancer 48: 1353–1362, 1981.

    Article  PubMed  CAS  Google Scholar 

  124. Price FB, Hewlet JS, Deodar SD, Barna B: The therapy of malignant melanoma with transfer factor: A preliminary report. Cleve Clin Q 41: 1–4, 1974.

    PubMed  CAS  Google Scholar 

  125. Toivanen A, Lassila O, Nordman E: Lack of effect of Levamisole on the immune function in melanoma patients. Cancer Immunol Immunother 10: 191–195, 1981.

    Article  Google Scholar 

  126. Thatcher N, Swindell R, Crowther D: Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma: A sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. Clin Exp Immunol 35: 36–44, 1979.

    PubMed  CAS  Google Scholar 

  127. Thatcher N, Swindell R, Crowther D: Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma: A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions. Clin Exp Immunol 35: 171–179, 1979.

    PubMed  CAS  Google Scholar 

  128. Krown SE, Burk M, Kirkwood JM, et al: The American Cancer Society clinical trial of human leukocyte interferon in malignant melanoma: Preliminary results. In: The biology of the interferon system, DeMaeyer E, Galasso G, Schellekens H (eds). New York, Amsterdam, Oxford: Elsevier North Holland Biomedical Press, 1981, pp 397–400.

    Google Scholar 

  129. Priestman T, Retsas S, Newton K, Westbury G: A Phase II evaluation of Wellcome HuIFN in advanced malignant melanoma. In: The biology of the interferon system, DeMaeyer E, Galasso G, Schellekens H (eds). New York, Amsterdam, Oxford: Elsevier North Holland Biomedical Press, 1981, pp 421–424.

    Google Scholar 

  130. Gutterman JU, Mavligit G, Gottlieb JA, et al: Chemoimmunotherapy of disseminated malignant melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guerin. N Engl J Med 291: 592–597, 1974.

    Article  PubMed  CAS  Google Scholar 

  131. Oguro M, Takagi T, Majima H, Ishiguro K: Immunochemotherapy of malignant melanoma with BCG cell-wall skeleton. Gann Monogr Cancer Res 21: 225–230, 1978.

    Google Scholar 

  132. Patt YZ, Hersh EM, Schafer LA, et al: The need for immune evaluation prior to thymosincontaining chemoimmunotheapy for melanoma. Cancer Immunol Immunother 7: 131–136, 1979.

    Article  Google Scholar 

  133. Ikonopisov, RL, Lewis MG, Hunter–Craig ID, et al: Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J 2: 752–754, 1970.

    Article  PubMed  CAS  Google Scholar 

  134. Currie GA, LeJuene F, Hamilton-Fairley G: Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J 2: 305–310, 1971.

    Article  PubMed  CAS  Google Scholar 

  135. Currie GA: Effect of active immunization with irradiated tumour cells on specific serum inhibitors of cell-mediated immunity in patients with disseminated cancer. Br J Cancer 28: 25–35, 1973.

    Article  PubMed  CAS  Google Scholar 

  136. Seigler HF, Shingleton WW, Metzgar RS, et al: Non-specific and specific immunotherapy in patients with melanoma. Surgery 72: 162–174, 1971.

    Google Scholar 

  137. Livingston PO, Oettgen HF, Old LJ: Specific active immunotherapy in cancer treatment. In: Immunological aspects of cancer therapeutics, Mihich E (ed). New York: John Wiley and Sons, Inc., 1982, pp 363–404.

    Google Scholar 

  138. Livingston PO, Watanabe T, Shiku H, et al: Serological response of melanoma patients receiving melanoma cell vaccines: I. Autologous cultured melanoma cells. Int J Cancer 30: 413–422, 1982.

    Article  PubMed  CAS  Google Scholar 

  139. Livingston PO, Takeyama H, Pollack MS, et al: Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 31:567– 575, 1983.

    Article  PubMed  CAS  Google Scholar 

  140. Irie RF, Giuliano AE, Morton DL: Oncofetal antigen: A tumor-associated fetal antigen immunogenic in man. J Natl Cancer Inst 63: 367–373, 1979.

    PubMed  CAS  Google Scholar 

  141. Currie GA, McElwain TJ: Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: A pilot study. Br J Cancer 31: 143–146, 1975.

    Article  PubMed  CAS  Google Scholar 

  142. Newlands ES, Oon CJ, Roberts JT, et al: Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34: 174–179, 1976.

    Article  PubMed  CAS  Google Scholar 

  143. Berkelhammer J, Mastrangelo MJ, Bellet RE, et al: Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients. Europ J Cancer 45: 197–204, 1978.

    Google Scholar 

Download references

Authors
  1. Carl M. Pinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematology/Oncology Cancer Center, University of Texas Medical Branch, Galveston, Texas, USA

    John J. Costanzi

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Pinsky, C.M. (1984). The Immunology and Immunotherapy of Human Malignant Melanoma. In: Costanzi, J.J. (eds) Clinical Management of Malignant Melanoma. Cancer Treatment and Research, vol 21. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3813-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3813-0_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3815-4

  • Online ISBN: 978-1-4613-3813-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation